LPLD Registry, observational longitudinal pharmaco-epidemiologic study in lipoprotein lipase deficient (LPLD) patients, either treated or not treated with alipogene tiparvovec (Glybera)

Trial Profile

LPLD Registry, observational longitudinal pharmaco-epidemiologic study in lipoprotein lipase deficient (LPLD) patients, either treated or not treated with alipogene tiparvovec (Glybera)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Alipogene tiparvovec (Primary)
  • Indications Hyperlipoproteinaemia type I
  • Focus Adverse reactions
  • Acronyms GENIALL
  • Sponsors uniQure
  • Most Recent Events

    • 25 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top